Cargando…

Tropomyosins: Potential Biomarkers for Urothelial Bladder Cancer

Despite the incidence and prevalence of urothelial bladder cancer (UBC), few advances in treatment and diagnosis have been made in recent years. In this review, we discuss potential biomarker candidates: the tropomyosin family of genes, encoded by four loci in the human genome. The expression of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Humayun-Zakaria, Nada, Arnold, Roland, Goel, Anshita, Ward, Douglas, Savill, Stuart, Bryan, Richard T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429115/ https://www.ncbi.nlm.nih.gov/pubmed/30836651 http://dx.doi.org/10.3390/ijms20051102

Ejemplares similares

Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?
por: Humayun-Zakaria, Nada, et al.
Publicado: (2021)

STAG2 Protein Expression in Non–muscle-invasive Bladder Cancer: Associations with Sex, Genomic and Transcriptomic Changes, and Clinical Outcomes
por: Gordon, Naheema S., et al.
Publicado: (2022)

Tropomyosin Is Potential Markers for the Diagnosis and Prognosis of Bladder Cancer
por: Yan, Yunkun, et al.
Publicado: (2022)

A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer
por: D’Costa, Jamie J., et al.
Publicado: (2016)

Urinary EpCAM in urothelial bladder cancer patients: characterisation and evaluation of biomarker potential
por: Bryan, R T, et al.
Publicado: (2014)

Urothelial Bladder Cancer Urinary Biomarkers
por: Noon, Aidan P, et al.
Publicado: (2014)

Prioritizing potential circRNA biomarkers for bladder cancer and bladder urothelial cancer based on an ensemble model
por: Su, Qiongli, et al.
Publicado: (2022)

Inflammatory Adipokines Decrease Expression of Two High Molecular Weight Isoforms of Tropomyosin Similar to the Change in Type 2 Diabetic Patients
por: Savill, Stuart A., et al.
Publicado: (2016)

Back-Splicing Transcript Isoforms (Circular RNAs) Affect Biologically Relevant Pathways and Offer an Additional Layer of Information to Stratify NMIBC Patients
por: Goel, Anshita, et al.
Publicado: (2020)

MRE11A Isoform Expression Associated with Outcome Following Radiotherapy in Muscle-Invasive Bladder Cancer does not Alter Cell Survival and DNA Double-Strand Break Repair Following Ionising Radiation
por: Walker, Alexandra K., et al.
Publicado: (2019)

Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
por: Togneri, Fiona S, et al.
Publicado: (2016)

Defining the frequency of human papillomavirus and polyomavirus infection in urothelial bladder tumours
por: Llewellyn, Matthew A., et al.
Publicado: (2018)

PLAUR as a Potential Biomarker Associated with Immune Infiltration in Bladder Urothelial Carcinoma
por: Liu, Mulin, et al.
Publicado: (2021)

Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers
por: Yang, Alexander, et al.
Publicado: (2020)

Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes
por: Goel, Anshita, et al.
Publicado: (2022)

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer
por: Kerzeli, Iliana K., et al.
Publicado: (2023)

Tropomyosin antibody: the specific localization of tropomyosin in nonmuscle cells
Publicado: (1975)

Liquid biopsies for bladder cancer
por: Ward, Douglas G., et al.
Publicado: (2017)

Cytoskeletal Tropomyosin as a Biomarker in Clostridium difficile Infection
por: Usacheva, Elena A., et al.
Publicado: (2019)

Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications
por: Minoli, Martina, et al.
Publicado: (2020)

Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker()
por: Li, Wei Tse, et al.
Publicado: (2018)

Mutational analysis of Ras hotspots in patients with urothelial carcinoma of the bladder
por: Tripathi, Kiran, et al.
Publicado: (2020)

The Tropomyosin Family as Novel Biomarkers in Relation to Poor Prognosis in Glioma
por: Huang, Ke, et al.
Publicado: (2022)

Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer
por: Aydin, Ahmet Murat, et al.
Publicado: (2017)

Sonic Hedgehog Expression is Associated with Lymph Node Invasion in Urothelial Bladder Cancer
por: Nedjadi, Taoufik, et al.
Publicado: (2018)

cGMP interacts with tropomyosin and downregulates actin-tropomyosin-myosin complex interaction
por: Zou, Lihui, et al.
Publicado: (2018)

Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity
por: Tabaei, Samira, et al.
Publicado: (2023)

Pancancer Analysis of Neurovascular-Related NRP Family Genes as Potential Prognostic Biomarkers of Bladder Urothelial Carcinoma
por: Deng, Chao, et al.
Publicado: (2021)

Regulation of endothelial permeability and transendothelial migration of cancer cells by tropomyosin-1 phosphorylation
por: Simoneau, Bryan, et al.
Publicado: (2012)

Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM
por: Bryan, R T, et al.
Publicado: (2015)

Bladder Cancer and Urothelial Impairment: The Role of TRPV1 as Potential Drug Target
por: Mistretta, Francesco, et al.
Publicado: (2014)

Cost of illness of urothelial bladder cancer in Italy
por: Gerace, Claudio, et al.
Publicado: (2017)

Penile metastasis secondary to urothelial bladder cancer
por: Dolny, Maciej, et al.
Publicado: (2023)

Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancer
por: Seiler, Roland, et al.
Publicado: (2010)

Research Advances in the Role of the Tropomyosin Family in Cancer
por: Meng, Yucheng, et al.
Publicado: (2023)

Oncological impact of inflammatory biomarkers in elderly patients treated with radical cystectomy for urothelial bladder cancer
por: Mari, Andrea, et al.
Publicado: (2020)

Tropomyosin keeps actin tough
por: Dove, Alan W.
Publicado: (2002)

Preliminary evaluation of urinary soluble Met as a Biomarker for urothelial carcinoma of the bladder
por: McNeil, Brian K, et al.
Publicado: (2014)

A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma
por: Wang, Xiang, et al.
Publicado: (2019)

Tropomodulin: a cytoskeletal protein that binds to the end of erythrocyte tropomyosin and inhibits tropomyosin binding to actin
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_eih6vqmmsv11t57pr2eltvcf79